Arteriocyte is now a part of Isto Biologics.

News + Views


ISTO Technologies to Participate in the Noble Financial Capital Markets BIOX Life Sciences Exposition

Sep 17, 2012

St. Louis, MO – September 17, 2012 – ISTO Technologies, Inc., a privately-held orthobiologics company, announced today that Mitchell Seyedin, Ph. D., President and Chief Executive Officer, will participate as a panelist and presenter in the Noble Financial Capital Markets BIOX Life Sciences Exposition in Stamford, CT. The panel presentation, “The Explosion of a New Industry – Tissue Engineering & Biomaterials,” will take place on Monday, September 24th at 3:30 p.m. ET.

Following the event, a high-definition video webcast of ISTO’s presentation and copies of the presentation materials will be available on the Company’s website, or through the Noble Financial websites:, or The Microsoft SilverLight web-browser plug-in is required to view the webcast replay (a download is available thru the presentation link). The webcast will be archived on for 90 days following the event.

ISTO’s proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged tissue. The Company’s two clinical-stage cell-based products, DeNovo® ET and NuQu®, potentially represent breakthrough technologies addressing two significant unmet medical needs: damaged knee cartilage and discogenic back pain. These products utilize juvenile chondrocytes that have a proven superior capacity for cartilage regeneration compared to adult cells. Additionally, ISTO’s patented cell-expansion process allows for a scalable, off-the-shelf solution not possible with autologous cell-based technologies.

DeNovo ET, a scaffold-free engineered cartilage tissue, is intended for the repair of damaged articular cartilage in the knee. DeNovo ET is being developed in partnership with Zimmer Inc.

NuQu is a non-surgical juvenile chondrocyte therapy for early intervention and restoration of disc function in patients suffering from discogenic back pain. This minimally-invasive ambulatory treatment potentially represents a breakthrough and cost-effective solution for discogenic back pain. There is currently no effective treatment available for intervertebral disc repair.

In addition to ISTO’s cell-based cartilage programs, the company is currently producing and marketing, InQu®, a differentiated bone graft extender and substitute. InQu combines integrated hyaluronic acid and a synthetic polymer for better handling and biology. The primary target market for the product is spinal fusion applications. InQu has been used in over 17,000 surgeries at U.S. hospitals to date.

About ISTO
ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at

About Noble Financial
Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in New York, Boston, New Jersey, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 150 presenting companies from across North America and total attendance of close to 600. For more information:

To top